Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.

Biomarkers for Homologous Recombination Deficiency in Cancer

Hoppe, Michal M, Sundar, Raghav, Tan, David S P, Jeyasekharan, Anand D · 2018 · JNCI: Journal of the National Cancer Institute

Abstract

Defective DNA repair is a common hallmark of cancer. Homologous recombination is a DNA repair pathway of clinical interest due to the sensitivity of homologous recombination-deficient cells to poly-ADP ribose polymerase (PARP) inhibitors. The measurement of homologous recombination deficiency (HRD) in cancer is therefore vital to the appropriate design of clinical trials incorporating PARP inhibitors. However, methods to identify HRD in tumors are varied and controversial. Understanding existing and new methods to measure HRD is important to their appropriate use in clinical trials and practice. The aim of this review is to summarize the biology and clinical validation of current methods to measure HRD, to aid decision-making for patient stratification and translational research in PARP inhibitor trials. We discuss the current clinical development of PARP inhibitors, along with established indicators for HRD such as germline BRCA1/2 mutation status and clinical response to platinum-based therapy. We then examine newer assays undergoing clinical validation, including 1) somatic mutations in homologous recombination genes, 2) "genomic scar" assays using array-based comparative genomic hybridization (aCGH), single nucleotide polymorphism (SNP) analysis or mutational signatures derived from next-generation sequencing, 3) transcriptional profiles of HRD, and 4) phenotypic or functional assays of protein expression and localization. We highlight the strengths and weaknesses of each of these assays, for consideration during the design of studies involving PARP inhibitors.

Overview

Integrity signals

Registry

Crossref · 10.1093/jnci/djy085

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 116 references

Cited by

See all 329

Metadata

Authors
Hoppe, M. M., Sundar, R., Tan, D. S. P., & Jeyasekharan, A. D.
Affiliations
  • Cancer Science Institute of Singapore, National University Hospital, Singapore
  • National University Hospital (SG)
  • National University Cancer Institute, Singapore (SG)
Corresponding author
  • Tan, David S P
  • Jeyasekharan, Anand D
Venue
JNCI: Journal of the National Cancer Institute
Published
2018-05-18
Volume
110
Issue
7
Pages
704-713
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2804007674
Cited by
329
References
116
Citations by year
2026: 23 · 2025: 35 · 2024: 35 · 2023: 49 · 2022: 69 · 2021: 57 · 2020: 47 · 2019: 11 · 2018: 3
FWCI
3.11
Type
journal article
Language
en
Open access
closed
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Medical Research Council
  • MOH Healthcare Research
  • Cancer Science Institute
  • Singapore Ministry of Health's National Medical Research Council (NMRC/CIRG/1400/2014)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Keywords
homologous recombination deficiency, PARP inhibitors, DNA repair deficiency, biomarkers, BRCA mutations, platinum sensitivity, mutational signatures, gene expression profiling, patient stratification, clinical trial design, homologous recombination genes
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Decision Support Techniques, DNA Repair, Genetic Testing, Humans, Neoplasms, Biomarkers, Tumor, Patient Selection, DNA Repair-Deficiency Disorders, Validation Studies as Topic, Homologous Recombination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biomarkers for Homologous Recombination Deficiency in Cancer. https://app.cochat.ai/papers/10.1093/jnci/djy085
The paper
Hoppe, M. M., Sundar, R., Tan, D. S. P., & Jeyasekharan, A. D. (2018). Biomarkers for Homologous Recombination Deficiency in Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djy085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.